• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

50.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 292
Open 50.86
Bid (Size) 20.35 (200)
Ask (Size) 81.37 (200)
Prev. Close 50.86
Today's Range 50.86 - 50.86
52wk Range 29.16 - 57.65
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
February 22, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
February 17, 2026
Via Investor Brand Network
Topics Intellectual Property

Performance

YTD
+2.8%
+2.8%
1 Month
+5.4%
+5.4%
3 Month
+12.6%
+12.6%
6 Month
+14.5%
+14.5%
1 Year
+55.6%
+55.6%

More News

Read More
News headline image
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
February 16, 2026
Via StockStory
Topics Stocks Supply Chain
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
February 17, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
February 12, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 We Brush Off
February 08, 2026
Via StockStory
News headline image
1 Healthcare Stock to Consider Right Now and 2 We Brush Off
January 28, 2026
Via StockStory
Topics Stocks
News headline image
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
January 25, 2026
Via StockStory
News headline image
3 Unprofitable Stocks We Steer Clear Of
January 21, 2026
Via StockStory
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
January 15, 2026
Via Chartmill
News headline image
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
January 01, 2026
Via MarketMinute
News headline image
3 Low-Volatility Stocks We’re Skeptical Of
December 31, 2025
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks That Concern Us
December 22, 2025
Via StockStory
News headline image
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗
December 19, 2025
Via Stocktwits
Topics Cannabis ETFs Government
News headline image
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back ↗
December 15, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down
December 14, 2025
Via StockStory
News headline image
3 Stocks Under $50 That Concern Us
December 11, 2025
Via StockStory
News headline image
3 Unprofitable Stocks We Find Risky
December 03, 2025
Via StockStory
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
December 03, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds
November 23, 2025
Via StockStory
Topics Stocks
News headline image
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 21, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
November 21, 2025
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
November 18, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
November 18, 2025
Via The Motley Fool
News headline image
3 Russell 2000 Stocks Walking a Fine Line
November 13, 2025
Via StockStory

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 50.86
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 02/20/26 04:00 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.70B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap